1、 RENNE S L,WOO H Y,ALLEGRA S,et al.Vessels pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma[J].Hepatology,2020 ,71(1):183-195. RENNE S L,WOO H Y,ALLEGRA S,et al.Vessels pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma[J].Hepatology,2020 ,71(1):183-195.
2、 LI M,YAN T,CAI Y,et al.Expression of matrix metalloproteinases and their association with clinical characteristics of solid tumors[J].Gene,2023(850):146927. LI M,YAN T,CAI Y,et al.Expression of matrix metalloproteinases and their association with clinical characteristics of solid tumors[J].Gene,2023(850):146927.
3、 FANG J H,ZHOU H C,ZHANG C,et al.A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner[J].Hepatology,2015,62(2):452-465. FANG J H,ZHOU H C,ZHANG C,et al.A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner[J].Hepatology,2015,62(2):452-465.
4、 WANG W H,STUDACH L L,ANDRISANI O M.Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus(HBV)X protein-mediated hepatocyte transformation and in HBV replication[J].Hepatology,2011,53(4):1137-1147. WANG W H,STUDACH L L,ANDRISANI O M.Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus(HBV)X protein-mediated hepatocyte transformation and in HBV replication[J].Hepatology,2011,53(4):1137-1147.
5、 LEE W,TECKIE S,WIESNER T,et al.PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors[J].Nat Genet,2014,46(11):1227-1232. LEE W,TECKIE S,WIESNER T,et al.PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors[J].Nat Genet,2014,46(11):1227-1232.
6、 XIA R,JIN FY,LU K,et al.SUZ12 promotes gastric cancer cell proliferation and metastasis by regulatingKLF2 and E-cadherin[J].Tumour Biol,2015,36(7):5341-5351. XIA R,JIN FY,LU K,et al.SUZ12 promotes gastric cancer cell proliferation and metastasis by regulatingKLF2 and E-cadherin[J].Tumour Biol,2015,36(7):5341-5351.
7、 LIU C,SHI X,WANG L,et al.SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis[J].Tumour Biol,2014,35(6):6073-6082. LIU C,SHI X,WANG L,et al.SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis[J].Tumour Biol,2014,35(6):6073-6082.
8、 WU Y,HU H,ZHANG W,et al.SUZ12 is a novel putative oncogene promoting tumorigenesis in head and neck squamous cell carcinoma[J].J Cell Mol Med,2018,22(7):3582-3594. WU Y,HU H,ZHANG W,et al.SUZ12 is a novel putative oncogene promoting tumorigenesis in head and neck squamous cell carcinoma[J].J Cell Mol Med,2018,22(7):3582-3594.
9、 MORSE M A,SUN W,KIM R,et al.The role of angiogenesis in hepatocellular carcinoma[J].Cancer Res,2019,25(3):912-920. MORSE M A,SUN W,KIM R,et al.The role of angiogenesis in hepatocellular carcinoma[J].Cancer Res,2019,25(3):912-920.
10、 ORLANDI P,SOLINI A,BANCHI M,et al.Antiangiogenic drugs in NASH:Evidence of a possible new therapeutic approach[J].Pharmaceuticals(Basel).2021,14(10):995. ORLANDI P,SOLINI A,BANCHI M,et al.Antiangiogenic drugs in NASH:Evidence of a possible new therapeutic approach[J].Pharmaceuticals(Basel).2021,14(10):995.
11、 HANAHAN D,FOLKMAN J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364. HANAHAN D,FOLKMAN J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
12、 FANG J H,XU L,SHANG L R,et al.Vessels That Encapsulate Tumor Clusters(VETC)pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma[J].Hepatology,2019,70(3):824-839. FANG J H,XU L,SHANG L R,et al.Vessels That Encapsulate Tumor Clusters(VETC)pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma[J].Hepatology,2019,70(3):824-839.
13、 HANAHAN D,WEINBERG R A.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674. HANAHAN D,WEINBERG R A.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
14、 XUE C,WANG K,JIANG X,et al.The down-regulation of SUZ12 accelerates the migration and invasion of liver cancer cells via activating ERK1/2 pathway[J].J Cancer,2019,10(6):1375-1384. XUE C,WANG K,JIANG X,et al.The down-regulation of SUZ12 accelerates the migration and invasion of liver cancer cells via activating ERK1/2 pathway[J].J Cancer,2019,10(6):1375-1384.
15、 STUDACH LL,MENNE S,CAIRO S,et al.Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein[J].Hepatology,2012,56(4):1240-1251. STUDACH LL,MENNE S,CAIRO S,et al.Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein[J].Hepatology,2012,56(4):1240-1251.
16、 LEVRERO M,ZUCMAN-ROSSI J.Mechanisms of HBV-induced hepatocellular carcinoma[J].J HEPATOL,2016,64(1 Suppl):S84-S101. LEVRERO M,ZUCMAN-ROSSI J.Mechanisms of HBV-induced hepatocellular carcinoma[J].J HEPATOL,2016,64(1 Suppl):S84-S101.
17、 YANG J D,HAINAUT P,GORES G J,et al.A global view of hepatocellular carcinoma:trends,risk,prevention and management[J].Nat Rev Gastroenterol Hepatol,2019,16(10):589-604. YANG J D,HAINAUT P,GORES G J,et al.A global view of hepatocellular carcinoma:trends,risk,prevention and management[J].Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.
18、 ANWANWAN D,SINGH S K,SINGH S,et al.Challenges in liver cancer and possible treatment approaches[J].Biochim Biophys Acta Rev Cancer 2020,1873(1),188314. ANWANWAN D,SINGH S K,SINGH S,et al.Challenges in liver cancer and possible treatment approaches[J].Biochim Biophys Acta Rev Cancer 2020,1873(1),188314.
19、 LLOVET J M,de BAERE T,KULIK L,et al.Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J].Nat Rev Gastroenterol Hepatol 2021,18(5),293-313. LLOVET J M,de BAERE T,KULIK L,et al.Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J].Nat Rev Gastroenterol Hepatol 2021,18(5),293-313.
20、 SHI J F,CAO M,WANG Y,et al.Is it possible to halve the incidence of liver cancer in China by 2050?[J] Int J Cancer 2021,148(5),1051-1065. SHI J F,CAO M,WANG Y,et al.Is it possible to halve the incidence of liver cancer in China by 2050?[J] Int J Cancer 2021,148(5),1051-1065.
21、 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231. 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
22、 SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249. SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
